Connection

Co-Authors

This is a "connection" page, showing publications co-authored by COLIN P DINNEY and XIFENG WU.
Connection Strength

3.412
  1. Genetic Variants in the Wnt/?-Catenin Signaling Pathway as Indicators of Bladder Cancer Risk. J Urol. 2015 Dec; 194(6):1771-6.
    View in: PubMed
    Score: 0.136
  2. Genetic variations in micro-RNA biogenesis genes and clinical outcomes in non-muscle-invasive bladder cancer. Carcinogenesis. 2013 May; 34(5):1006-11.
    View in: PubMed
    Score: 0.115
  3. Genetic variations in the transforming growth factor beta pathway as predictors of bladder cancer risk. PLoS One. 2012; 7(12):e51758.
    View in: PubMed
    Score: 0.114
  4. Association of polymorphisms in oxidative stress genes with clinical outcomes for bladder cancer treated with Bacillus Calmette-Gu?rin. PLoS One. 2012; 7(6):e38533.
    View in: PubMed
    Score: 0.110
  5. Intake of red meat and heterocyclic amines, metabolic pathway genes and bladder cancer risk. Int J Cancer. 2012 Oct 15; 131(8):1892-903.
    View in: PubMed
    Score: 0.108
  6. Use of fluorescence in situ hybridization to predict response to bacillus Calmette-Gu?rin therapy for bladder cancer: results of a prospective trial. J Urol. 2012 Mar; 187(3):862-7.
    View in: PubMed
    Score: 0.107
  7. A genome-wide association study identifies a locus on chromosome 14q21 as a predictor of leukocyte telomere length and as a marker of susceptibility for bladder cancer. Cancer Prev Res (Phila). 2011 Apr; 4(4):514-21.
    View in: PubMed
    Score: 0.101
  8. A multiplexed, particle-based flow cytometric assay identified plasma matrix metalloproteinase-7 to be associated with cancer-related death among patients with bladder cancer. Cancer. 2010 Oct 01; 116(19):4513-9.
    View in: PubMed
    Score: 0.098
  9. Genetic variations of the PI3K-AKT-mTOR pathway and clinical outcome in muscle invasive and metastatic bladder cancer patients. Carcinogenesis. 2010 Aug; 31(8):1387-91.
    View in: PubMed
    Score: 0.096
  10. Energy balance, the PI3K-AKT-mTOR pathway genes, and the risk of bladder cancer. Cancer Prev Res (Phila). 2010 Apr; 3(4):505-17.
    View in: PubMed
    Score: 0.094
  11. Genetic variations in PI3K-AKT-mTOR pathway and bladder cancer risk. Carcinogenesis. 2009 Dec; 30(12):2047-52.
    View in: PubMed
    Score: 0.092
  12. Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer. Nat Genet. 2009 Sep; 41(9):991-5.
    View in: PubMed
    Score: 0.090
  13. Dietary intake of vegetables and fruits and the modification effects of GSTM1 and NAT2 genotypes on bladder cancer risk. Cancer Epidemiol Biomarkers Prev. 2009 Jul; 18(7):2090-7.
    View in: PubMed
    Score: 0.089
  14. Benzo(a)pyrene diol epoxide-induced chromosome 9p21 aberrations are associated with increased risk of bladder cancer. Cancer Epidemiol Biomarkers Prev. 2008 Sep; 17(9):2445-50.
    View in: PubMed
    Score: 0.085
  15. Plasma vitamins E and A and risk of bladder cancer: a case-control analysis. Cancer Causes Control. 2008 Nov; 19(9):981-92.
    View in: PubMed
    Score: 0.083
  16. Evaluation of genetic variants in microRNA-related genes and risk of bladder cancer. Cancer Res. 2008 Apr 01; 68(7):2530-7.
    View in: PubMed
    Score: 0.082
  17. Profiling of genetic variations in inflammation pathway genes in relation to bladder cancer predisposition. Clin Cancer Res. 2008 Apr 01; 14(7):2236-44.
    View in: PubMed
    Score: 0.082
  18. Sensitivity to epidermal growth factor receptor inhibitor requires E-cadherin expression in urothelial carcinoma cells. Clin Cancer Res. 2008 Mar 01; 14(5):1478-86.
    View in: PubMed
    Score: 0.082
  19. Projecting individualized probabilities of developing bladder cancer in white individuals. J Clin Oncol. 2007 Nov 01; 25(31):4974-81.
    View in: PubMed
    Score: 0.080
  20. Telomere dysfunction in peripheral lymphocytes as a potential predisposition factor for renal cancer. J Urol. 2007 Oct; 178(4 Pt 1):1492-6.
    View in: PubMed
    Score: 0.079
  21. Risk assessment of renal cell carcinoma using alkaline comet assay. Cancer. 2007 Jul 15; 110(2):282-8.
    View in: PubMed
    Score: 0.078
  22. Dietary isothiocyanates, GSTM1, GSTT1, NAT2 polymorphisms and bladder cancer risk. Int J Cancer. 2007 May 15; 120(10):2208-13.
    View in: PubMed
    Score: 0.077
  23. Matrix metalloproteinase polymorphisms are associated with bladder cancer invasiveness. Clin Cancer Res. 2007 May 01; 13(9):2614-20.
    View in: PubMed
    Score: 0.077
  24. High-order interactions among genetic variants in DNA base excision repair pathway genes and smoking in bladder cancer susceptibility. Cancer Epidemiol Biomarkers Prev. 2007 Jan; 16(1):84-91.
    View in: PubMed
    Score: 0.075
  25. Genetic polymorphism in bladder cancer. Front Biosci. 2007 Jan 01; 12:192-213.
    View in: PubMed
    Score: 0.075
  26. Matrix metalloproteinase polymorphisms and bladder cancer risk. Cancer Res. 2006 Dec 15; 66(24):11644-8.
    View in: PubMed
    Score: 0.075
  27. Genotypes, haplotypes and diplotypes of XPC and risk of bladder cancer. Carcinogenesis. 2007 Mar; 28(3):698-703.
    View in: PubMed
    Score: 0.074
  28. E-cadherin promoter polymorphism (C-160A) and risk of recurrence in patients with superficial bladder cancer. Clin Genet. 2006 Sep; 70(3):240-5.
    View in: PubMed
    Score: 0.074
  29. Personal permanent hair dye use is not associated with bladder cancer risk: evidence from a case-control study. Cancer Epidemiol Biomarkers Prev. 2006 Sep; 15(9):1746-9.
    View in: PubMed
    Score: 0.074
  30. Bladder cancer risk as modified by family history and smoking. Cancer. 2006 Aug 15; 107(4):705-11.
    View in: PubMed
    Score: 0.073
  31. Bladder cancer predisposition: a multigenic approach to DNA-repair and cell-cycle-control genes. Am J Hum Genet. 2006 Mar; 78(3):464-79.
    View in: PubMed
    Score: 0.071
  32. The pharmacogenetic impact of inflammatory genes on bladder cancer recurrence. Pharmacogenomics. 2005 Sep; 6(6):575-84.
    View in: PubMed
    Score: 0.069
  33. Polymorphisms in inflammation genes and bladder cancer: from initiation to recurrence, progression, and survival. J Clin Oncol. 2005 Aug 20; 23(24):5746-56.
    View in: PubMed
    Score: 0.069
  34. Roles of tumor suppressor and telomere maintenance genes in cancer and aging--an epidemiological study. Carcinogenesis. 2005 Oct; 26(10):1741-7.
    View in: PubMed
    Score: 0.067
  35. Nucleotide excision repair gene polymorphisms and recurrence after treatment for superficial bladder cancer. Clin Cancer Res. 2005 Feb 15; 11(4):1408-15.
    View in: PubMed
    Score: 0.066
  36. Focus on bladder cancer. Cancer Cell. 2004 Aug; 6(2):111-6.
    View in: PubMed
    Score: 0.064
  37. Genetic instability in bladder cancer assessed by the comet assay. J Natl Cancer Inst. 2003 Apr 02; 95(7):540-7.
    View in: PubMed
    Score: 0.058
  38. Genome-wide association study identifies variants in casein kinase II (CSNK2A2) to be associated with leukocyte telomere length in a Punjabi Sikh diabetic cohort. Circ Cardiovasc Genet. 2014 Jun; 7(3):287-95.
    View in: PubMed
    Score: 0.031
  39. Genome-wide association study identifies multiple loci associated with bladder cancer risk. Hum Mol Genet. 2014 Mar 01; 23(5):1387-98.
    View in: PubMed
    Score: 0.030
  40. Fluid intake, genetic variants of UDP-glucuronosyltransferases, and bladder cancer risk. Br J Cancer. 2013 Jun 11; 108(11):2372-80.
    View in: PubMed
    Score: 0.029
  41. Genetic variants in telomere-maintenance genes and bladder cancer risk. PLoS One. 2012; 7(2):e30665.
    View in: PubMed
    Score: 0.027
  42. A genome-wide association study of bladder cancer identifies a new susceptibility locus within SLC14A1, a urea transporter gene on chromosome 18q12.3. Hum Mol Genet. 2011 Nov 01; 20(21):4282-9.
    View in: PubMed
    Score: 0.026
  43. A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci. Nat Genet. 2010 Nov; 42(11):978-84.
    View in: PubMed
    Score: 0.025
  44. Genetic variations in the sonic hedgehog pathway affect clinical outcomes in non-muscle-invasive bladder cancer. Cancer Prev Res (Phila). 2010 Oct; 3(10):1235-45.
    View in: PubMed
    Score: 0.024
  45. Genetic variants in cell cycle control pathway confer susceptibility to bladder cancer. Cancer. 2008 Jun; 112(11):2467-74.
    View in: PubMed
    Score: 0.021
  46. Modulation of DNA damage/DNA repair capacity by XPC polymorphisms. DNA Repair (Amst). 2008 Feb 01; 7(2):141-8.
    View in: PubMed
    Score: 0.020
  47. Organ preservation for muscle-invasive bladder cancer by transurethral resection. Urology. 2007 Sep; 70(3):473-6.
    View in: PubMed
    Score: 0.020
  48. High-order interactions among genetic polymorphisms in nucleotide excision repair pathway genes and smoking in modulating bladder cancer risk. Carcinogenesis. 2007 Oct; 28(10):2160-5.
    View in: PubMed
    Score: 0.020
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.